An overview of menopausal oestrogen-progestin hormone therapy and breast cancer risk.
about
Estradiol therapy and breast cancer risk in perimenopausal and postmenopausal women: a systematic review and meta-analysis.AGO Recommendations for Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. Update 2011.Use of exogenous hormones and the risk of breast cancer: results from self-reported survey data with validity assessment.Breast density and polymorphisms in genes coding for CYP1A2 and COMT: the Multiethnic Cohort.Progesterone action in human tissues: regulation by progesterone receptor (PR) isoform expression, nuclear positioning and coregulator expression.Characteristics and recent evolution of menopausal hormone therapy use in a cohort of Swedish womenMenopausal hormone therapy and subsequent risk of specific invasive breast cancer subtypes in the California Teachers Study.Risk factors of breast cancer: a systematic review and meta-analysis.Increased ovarian cancer risk associated with menopausal estrogen therapy is reduced by adding a progestin.Menopausal hormone therapy and other breast cancer risk factors in relation to the risk of different histological subtypes of breast cancer: a case-control study.Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort studyThe bioidentical hormone debate: are bioidentical hormones (estradiol, estriol, and progesterone) safer or more efficacious than commonly used synthetic versions in hormone replacement therapy?Risk of breast cancer by type of menopausal hormone therapy: a case-control study among post-menopausal women in France.Hormonal therapy and risk of breast cancer in mexican women.Does hormone therapy counter the beneficial effects of physical activity on breast cancer risk in postmenopausal women?Lowering oral contraceptive norethindrone dose increases estrogen and progesterone receptor levels with no reduction in proliferation of breast epithelium: a randomized trial.Exogenous estrogen protects mice from the consequences of obesity and alcohol.Oral progestagens before menopause and breast cancer risk.The risk of breast, endometrial and ovarian cancer in users of hormonal preparations.Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer.Current breast cancer risks of hormone replacement therapy in postmenopausal women.Sleep duration, melatonin and breast cancer among Chinese women in Singapore.Breast cancer risk factors in a defined population: weighted logistic regression approach for rare events.Review of the etiology of breast cancer with special attention to organochlorines as potential endocrine disruptors.Estrogen plus progestin therapy and breast cancer in recently postmenopausal women.Menopausal hormone therapy and breast cancer: what is the true size of the increased risk?Vaginal Estrogen Therapy for Patients with Breast Cancer.Identifying population-based approaches to lower breast cancer risk.Hormone replacement therapy and the risk of breast cancer.Vaginal estrogen therapy in postmenopausal breast cancer patients treated with aromatase inhibitors.The pharmacogenomics of sex hormone metabolism: breast cancer risk in menopausal hormone therapy.Relationship between prolactin, breast cancer risk, and antipsychotics in patients with schizophrenia: a critical review.Radiation-associated breast cancer and gonadal hormone exposure: a report from the Childhood Cancer Survivor Study.Postmenopausal hormone therapy and the risk of breast cancer in Norway.Combined hormone therapy at menopause and breast cancer: a warning--short-term use increases risk.Do the dose or route of administration of norethisterone acetate as a part of hormone therapy play a role in risk of breast cancer: national-wide case-control study from Finland.Change in risk of breast cancer after receiving hormone replacement therapy by considering effect-modifiers: a systematic review and dose-response meta-analysis of prospective studies.Risk of different histological types of postmenopausal breast cancer by type and regimen of menopausal hormone therapy.Breast cancer incidence trends in Norway--explained by hormone therapy or mammographic screening?Postmenopausal hormone therapy with estradiol and norethisterone acetate and mammographic density: findings from a cross-sectional study among Norwegian women.
P2860
Q30239742-B18B5209-051A-4943-83C5-A24053D3A3BDQ30318240-0BE17130-58C6-45EA-B292-2082EA32DA47Q31032088-069B4C00-DB77-41A7-9E10-08B389380128Q33273465-DDC527F2-4AC5-49ED-BD99-F2D08C92EC03Q33595229-83273B38-A82D-4A3E-8F45-B7CC197B865DQ33710365-A547CCC3-58AD-4DBF-B84C-3770C4AD8061Q34115930-12A00AD5-B265-4A41-9645-D62F2956877EQ34346863-F4950FA9-41E6-4590-9944-DA0515A9759BQ34372874-56845BB4-D906-4E5C-9965-12CB34E7F097Q34480625-E6CC6B20-C3F8-464A-97EC-DA38BBCE8906Q34576753-6592CF57-6520-4A7D-8829-CD5404CCBBE6Q34932849-ACF7A2C9-CF72-4072-A8C9-FFBC3E9110BDQ35040736-C14968A8-ED0F-4AEB-B443-CAEB9F7E690CQ35048651-B59AE660-F02E-42EA-A683-482AEFF4F4A0Q35588438-701FBDA9-FE33-4608-A45C-EE25ABC3A175Q35968796-F3BAEB54-5DC3-4888-A8E0-2E38E81FCFD5Q36113238-ECD32C84-D80C-443A-BD44-270F54993761Q36113902-A503E166-AEBD-44A3-9FA2-9183EEC2AFC4Q36447526-E7ABC89C-A8C4-4DAC-87A1-B6125015631AQ36593545-98D77B2C-1739-4B15-9075-0129B7687856Q36675379-8FA1AD4F-EBDE-465F-BE59-A4D7D86AC8E6Q36951983-C2C167B2-8BB4-4666-AB62-FDA793D66B9CQ36998145-7A70FA1B-7A66-4A84-BCE7-AF1CE1ECC2E4Q37119906-539E50B3-991F-4021-9936-632E262BF368Q37163009-5ACFECB7-EDEF-4BCA-886C-3D114A49E0C3Q37203133-D444D3D0-1062-42BC-A720-0CEB023D43B0Q37389691-A8A0A01C-BCAE-4856-8A1D-63F875263AC6Q37643427-946F5064-B5C9-4BF2-A5EB-7311121EEE34Q37909897-C1483095-5847-4A53-91F0-EEDCFF5D565EQ37972785-18BE46F8-DFC6-4CB6-8D6E-00CFF6F45A00Q38003702-0941E630-0C78-48A6-B3EE-05821AC937F4Q38538492-D46C705F-28BC-4B9D-9644-2D4464D0C8DBQ40152948-3C344B8C-39CC-4954-AE19-4DB72A947E9AQ40626144-611423D7-48CB-4CBA-91B8-334F828D6BADQ42920762-9DAFA308-1590-4F10-9F42-8C6C21856E97Q43254264-0DBBDD30-F6BE-49AF-9186-09F725A1F938Q44074291-EBE6002C-48DD-40BB-8287-B65660B27074Q44871715-F1E4491A-254F-4BF8-925D-E6C8CAC45C3CQ44957319-094E8063-EADC-4475-884C-E12088C33051Q45786935-BC4794CF-11EF-4C9E-9ECC-5D1AA74390E1
P2860
An overview of menopausal oestrogen-progestin hormone therapy and breast cancer risk.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
An overview of menopausal oestrogen-progestin hormone therapy and breast cancer risk.
@ast
An overview of menopausal oestrogen-progestin hormone therapy and breast cancer risk.
@en
type
label
An overview of menopausal oestrogen-progestin hormone therapy and breast cancer risk.
@ast
An overview of menopausal oestrogen-progestin hormone therapy and breast cancer risk.
@en
prefLabel
An overview of menopausal oestrogen-progestin hormone therapy and breast cancer risk.
@ast
An overview of menopausal oestrogen-progestin hormone therapy and breast cancer risk.
@en
P2093
P2860
P356
P1476
An overview of menopausal oestrogen-progestin hormone therapy and breast cancer risk.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.BJC.6602617
P407
P577
2005-06-01T00:00:00Z